Pharsight

Victrelis is owned by Merck Sharp Dohme.

Victrelis contains Boceprevir.

Victrelis has a total of 3 drug patents out of which 0 drug patents have expired.

Victrelis was authorised for market use on 13 May, 2011.

Victrelis is available in capsule;oral dosage forms.

Victrelis can be used as treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food, treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease.

The generics of Victrelis are possible to be released after 11 November, 2027.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43298	MERCK SHARP DOHME	Peptides as NS3-serine protease inhibitors of hepatitis C virus	Dec, 2024 (1 year, 8 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119602	MERCK SHARP DOHME	Administration of HCV protease inhibitors in combination with food to improve bioavailability	Mar, 2027 (3 years from now)
US7772178	MERCK SHARP DOHME	Pharmaceutical formulations and methods of treatment using the same	Nov, 2027 (4 years from now)

Drugs and Companies using BOCEPREVIR ingredient

Market Authorisation Date: 13 May, 2011

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in...

Dosage: CAPSULE;ORAL